Cagrilintide: Next-Gen Amylin Analog for Weight Loss (CagriSema)
Cagrilintide: The Amylin Analog That Could Be the Next Big Thing in Weight Loss
When semaglutide redefined what obesity medicine could achieve, researchers were already working on what might come next. Cagrilintide takes a completely different hormonal approach — targeting amylin rather than GLP-1 — and early data from its combination with semaglutide (a drug being called “CagriSema”) is producing weight loss numbers that rival or exceed tirzepatide. Here’s what we know, what we don’t, and why this matters.
Quick Answer: Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, currently in Phase III clinical trials. It works by mimicking amylin, a pancreatic hormone that helps regulate appetite and slows gastric emptying. In combination with semaglutide (as CagriSema), early trials showed up to 15–22% body weight reduction. It is not yet FDA-approved.
What Is Cagrilintide?
Cagrilintide is a synthetic, acylated analog of human amylin — a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to meals. Human amylin itself was used as the basis for pramlintide (Symlin), an FDA-approved diabetes medication, but pramlintide required multiple daily injections and was commercially limited due to inconvenience.
Cagrilintide is engineered for once-weekly dosing. It incorporates structural modifications including fatty acid chain attachment (acylation) to extend its half-life, allowing the same type of long-acting formulation strategy used for semaglutide and other modern GLP-1 analogs. It binds to amylin receptors (AMYR1, AMYR2, AMYR3) and also to calcitonin receptors, which are components of the amylin receptor complexes.
Novo Nordisk is the developer, and cagrilintide is part of their broader pipeline of next-generation obesity and metabolic disease therapies.
How Amylin Works in Weight Regulation
To understand cagrilintide, you need to understand what amylin does physiologically. After a meal, amylin is co-released with insulin from beta cells. It:
- Slows gastric emptying, extending the time food stays in the stomach and reducing post-meal blood glucose spikes
- Suppresses postprandial glucagon secretion
- Signals satiety through receptors in the area postrema and hypothalamus, reducing appetite and meal size
- May influence reward pathways related to food intake
People with type 2 diabetes and obesity often have impaired amylin secretion in addition to insulin resistance, which is one reason amylin replacement was hypothesized as potentially useful. The brain circuits for amylin-mediated satiety are distinct from (though overlapping with) GLP-1 receptor pathways, which is the key rationale for combining the two mechanisms.
Clinical Trial Data
Phase I and Phase II Trials
Early-stage trials established cagrilintide’s pharmacokinetics, tolerability, and dose-response for GLP-1 effects. A Phase II trial (Enebo et al., Lancet, 2021) tested cagrilintide as monotherapy for obesity in 706 adults. At the highest dose tested (4.5 mg weekly), participants lost an average of 10.8% of body weight over 26 weeks compared to 3.0% with placebo. These are meaningful results for monotherapy.
CagriSema: The Combination
The more exciting and more published data involves CagriSema — a fixed-ratio combination of cagrilintide and semaglutide. The rationale is complementarity: amylin and GLP-1 act through different (though overlapping) neural and peripheral circuits, potentially allowing additive appetite suppression.
A Phase II CagriSema trial published by Enebo and colleagues showed that the combination outperformed either component alone for weight loss. At the highest dose tested, CagriSema produced approximately 15–17% body weight reduction in adults with obesity over 32 weeks, with a particularly impressive proportion of participants achieving large weight reductions.
Phase III trials for CagriSema (the REDEFINE program) are underway. REDEFINE-1 (approximately 3,400 participants with obesity) is evaluating a 2.4 mg cagrilintide + 2.4 mg semaglutide combination against placebo and semaglutide alone. Interim data and full results from these trials will be critical for understanding the drug’s real-world benefit-risk profile.
How Cagrilintide Differs From GLP-1 Agonists
The distinction matters for understanding why combination therapy might add value:
GLP-1 agonists (semaglutide, liraglutide, tirzepatide’s GLP-1 component) primarily work by stimulating GLP-1 receptors on vagal nerve fibers, in the brainstem (area postrema), and in the hypothalamus to suppress appetite. They also slow gastric emptying and enhance glucose-dependent insulin secretion.
Amylin analogs act through separate receptor complexes (calcitonin receptor + RAMPs) in the area postrema and elsewhere, with somewhat different downstream signaling and neural circuit engagement. Rodent studies have long shown that amylin and GLP-1 combination produces greater food intake reduction than either alone (Clemmensen et al., Endocrinology, 2014).
This is the scientific basis for expecting additive — not merely duplicative — effects from the combination. Whether this translates to meaningfully greater benefit than tirzepatide (which uses a different dual mechanism) will depend on the full REDEFINE Phase III data.
Side Effect Profile
Based on published Phase II data and consistent with the amylin agonist class (pramlintide precedent), cagrilintide’s side effects are primarily:
- Nausea (the most common, dose-dependent, typically front-loaded during dose titration)
- Vomiting
- Diarrhea
- Decreased appetite (expected as an effect, but occasionally undesirably severe)
In the Phase II CagriSema trial, gastrointestinal side effects were more common than with semaglutide alone but appeared manageable with dose titration. Discontinuation rates were similar to GLP-1 monotherapy trials.
The calcitonin receptor component raises theoretical questions about calcitonin-like effects (calcitonin itself has roles in bone metabolism), but no adverse bone or thyroid signals have emerged in published trials. Long-term safety data is still being collected through Phase III.
Legal Status and Availability
Cagrilintide is not FDA-approved. It is currently in Phase III clinical trials (REDEFINE program) as part of the CagriSema combination. There is no legitimate pathway to access cagrilintide outside of a clinical trial.
Unlike many peptides discussed as research chemicals, cagrilintide is not widely available through gray-market peptide vendors — partly because it is a complex acylated peptide difficult to synthesize and formulate outside pharmaceutical manufacturing. Any product claiming to be cagrilintide sold online would be of unknown identity, purity, and potency.
The expected approval timeline, if Phase III results are positive, would likely be 2026–2027 based on trial timelines.
Comparing CagriSema to Tirzepatide
This comparison is premature until head-to-head data exists, but it’s worth understanding the landscape:
- Tirzepatide at 15 mg: ~22.5% average weight loss in SURMOUNT-1 (Jastreboff et al., NEJM, 2022)
- CagriSema at maximum tested Phase II dose: ~15–17% in Phase II (32 weeks)
- Phase III CagriSema data has not been published at time of writing
Early data suggests these may be comparable, with Phase III full results being decisive. The two drugs target entirely different hormone systems (GIP/GLP-1 vs. amylin/GLP-1), and future patients may have access to both as different treatment options based on tolerance and individual response.
What This Means for the Future of Obesity Treatment
The pipeline of dual and triple hormone agonists represents a genuine paradigm shift in obesity pharmacology. Alongside CagriSema, drugs like retatrutide (GLP-1/GIP/glucagon triple agonist) are in clinical development. The trajectory of these medications suggests that 25–30% or more body weight reduction through pharmacology may become achievable for many patients in the next few years.
This doesn’t mean these drugs are a panacea — the weight regain after discontinuation, the persistent cost and access barriers, and the need for long-term use all remain important issues. But from a scientific standpoint, the progress is remarkable.
Frequently Asked Questions
Can I participate in a cagrilintide clinical trial?
The REDEFINE program trials may still be enrolling at various sites. ClinicalTrials.gov is the best resource for finding active trials and eligibility criteria. Participation in clinical trials is a legitimate way to access investigational medications under medical supervision.
Is CagriSema going to replace semaglutide?
It will be complementary to rather than replacing semaglutide. Semaglutide (Ozempic/Wegovy) is already approved and widely used. CagriSema, if approved, would likely become an option for patients who need greater weight loss than semaglutide alone provides. The combination product could also command a premium price point, affecting access.
Does cagrilintide work without semaglutide?
The Phase II monotherapy data showed meaningful weight loss (~10.8% at 4.5 mg over 26 weeks). This is significant and better than earlier obesity drugs. However, the combination with semaglutide dramatically outperforms monotherapy, which is why Novo Nordisk is pursuing CagriSema as the primary clinical program rather than cagrilintide alone.
How does amylin relate to insulin?
Amylin is co-secreted with insulin from pancreatic beta cells in response to meals, in an approximately 1:100 molar ratio (amylin:insulin). People with type 1 diabetes lack both insulin and amylin; people with type 2 diabetes often have progressively impaired secretion of both. This is why amylin replacement was first explored in diabetes management with pramlintide.
What is the REDEFINE program?
REDEFINE is Novo Nordisk’s Phase III clinical trial program for CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly). Multiple trials are included: REDEFINE-1 tests the combination in obesity; REDEFINE-2 in obesity with type 2 diabetes; additional trials examine cardiovascular outcomes and other endpoints. These trials will determine whether CagriSema receives FDA and EMA approval.
Sources
- Enebo, L.B., Berthelsen, K.K., Kankam, M., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for obesity (SCALE CAGRISEMA): a randomised, participant-blind, physician-blind, placebo-controlled, phase 1b trial. Lancet, 397(10286), 1736–1748.
- Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216.
- Clemmensen, C., Chabenne, J., Finan, B., et al. (2014). GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes, 63(4), 1422–1427.
- Weyer, C., Fineman, M.S., Strobel, S., et al. (2001). Properties of pramlintide and insulin upon mixing. American Journal of Health-System Pharmacy, 62(8), 816–822.
- Novo Nordisk A/S. (2023). REDEFINE Program Overview. ClinicalTrials.gov identifiers NCT05567705, NCT05669547.
- Buse, J.B., Weyer, C., Maggs, D.G. (2002). Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clinical Diabetes, 20(3), 137–144.
Leave a Reply